EVAX
Evaxion Biotech A/S
NASDAQ · Healthcare · Biotechnology · DK
$3.12
+1.30%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.5M | 7.5M | 3.3M | 73.0K | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 7.5M | 7.5M | 3.3M | 73.0K | — |
| Operating Expenses | |||||
| R&D Expense | 10.3M | 10.0M | 10.5M | 11.9M | 17.1M |
| SG&A Expense | 5.6M | 6.5M | 7.3M | 10.1M | 8.1M |
| General & Admin Expense | 4.1M | 6.5M | 7.3M | 10.1M | 8.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 302.0K | 301.0K | 302.0K | 275.0K | 144.0K |
| Total Operating Expenses | 16.2M | 16.8M | 18.1M | 22.3M | 25.3M |
| Cost and Expenses | 16.2M | 16.8M | 18.1M | 22.3M | 25.3M |
| Operating Income (EBIT) | (8.7M) | (9.2M) | (14.7M) | (22.2M) | (25.3M) |
| Non-Operating | |||||
| Interest Income | (1.9M) | 299.0K | 254.0K | 154.0K | 2.8M |
| Interest Expense | 730.8K | 876.0K | 962.0K | 897.0K | 1.5M |
| Net Interest Income | (2.6M) | (577.0K) | (708.0K) | (743.0K) | 1.3M |
| Other Non-Op Income/Expense | (903.9K) | 619.0K | 3.4M | (718.0K) | 1.3M |
| Non-Operating Income (excl Interest) | 1.2M | (1.5M) | (4.3M) | (179.0K) | (2.1M) |
| EBT (Pre-Tax Income) | (9.6M) | (8.6M) | (11.4M) | (22.9M) | (23.9M) |
| Income Tax Expense | (940.7K) | (908.0K) | (788.0K) | (790.0K) | (772.0K) |
| Bottom Line | |||||
| Net Income | (8.7M) | (7.7M) | (10.6M) | (22.1M) | (23.2M) |
| Earnings from Cont. Ops | (8.7M) | (7.7M) | (10.6M) | (22.1M) | (23.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.7M) | (7.7M) | (10.6M) | (22.1M) | (23.2M) |
| Per Share | |||||
| Basic EPS | ($6.13) | ($1.21) | ($9.80) | ($32.40) | ($39.20) |
| Diluted EPS | ($6.13) | ($1.21) | ($9.80) | ($32.40) | ($39.20) |
| Revenue Per Share | $17.97 | $1.17 | $3.12 | $0.11 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 417010 | 6.4M | 1.1M | 683395 | 590967 |
| Diluted Shares Outstanding | 417010 | 6.4M | 1.1M | 683395 | 590967 |
| Profitability Metrics | |||||
| EBITDA | (9.9M) | (7.1M) | (9.8M) | (21.4M) | (22.6M) |
| D&A | — | 615.0K | 607.0K | 615.0K | 571.0K |
| EBIT | (9.9M) | (7.7M) | (10.4M) | (22.0M) | (23.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026